20 "Past Their Prime" Stocks to Dump From Your Portfolio

Wed., June 7th, 2023 | MarketBeat Staff

Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford, and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2023. Even 15 years ago, companies like Radio Shack, AOL, Yahoo, and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.

As the years go by, some companies lose their luster, and others rise to the top of the markets. We've already seen this in the last few decades, with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It's hard to know what the next mega-trend will be that knocks Apple, Google, and Amazon off the top rankings of the S&P 500, but we know that companies don't stay on the S&P 500 forever.

We have identified 20 companies that are past their prime. They aren't at risk of a near-term delisting from the S&P 500, but they show negative earnings growth for the next several years. If you own any of these stocks, consider whether they still belong in your portfolio before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.

#1 - Schrödinger (NASDAQ:SDGR)

Schrödinger, Inc, together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. Read More

Current Stock Price: $38.14
P/E Ratio: 293.4
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $50.00 (31.1% Upside)

#2 - Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. Read More

Current Stock Price: $36.12
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $58.08 (60.8% Upside)

#3 - Sprout Social (NASDAQ:SPT)

Sprout Social, Inc designs, develops, and operates a web-based social media management platform in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It provides cloud software that brings together social messaging, data, and workflows in a unified system of record, intelligence, and action. Read More

Current Stock Price: $47.61
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $64.36 (35.2% Upside)

#4 - Wolfspeed (NYSE:WOLF)

Wolfspeed, Inc is an innovator of Wolfspeed power and radio frequency (RF) semiconductors. Its Wolfspeed product families include silicon carbide materials, power-switching devices and RF devices targeted for applications such as electric vehicles, fast charging inverters, power supplies, telecom and military and aerospace. Read More

Current Stock Price: $49.48
Consensus Rating: Hold
Ratings Breakdown: 8 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $81.83 (65.4% Upside)

#5 - Coinbase Global (NASDAQ:COIN)

Coinbase Global, Inc provides financial infrastructure and technology for the cryptoeconomy in the United States and internationally. The company offers the primary financial account in the cryptoeconomy for retailers; a marketplace with a pool of liquidity for transacting in crypto assets for institutions; and technology and services that enable ecosystem partners to build crypto-based applications and securely accept crypto assets as payment. Read More

Current Stock Price: $51.61
Consensus Rating: Hold
Ratings Breakdown: 9 Buy Ratings, 11 Hold Ratings, 6 Sell Ratings.
Consensus Price Target: $61.48 (19.1% Upside)

#6 - monday.com (NASDAQ:MNDY)

monday.com Ltd., together with its subsidiaries, develops software applications in the United States, Europe, the Middle East, Africa, and internationally. It provides Work OS, a cloud-based visual work operating system that consists of modular building blocks used and assembled to create software applications and work management tools. Read More

Current Stock Price: $179.31
Consensus Rating: Buy
Ratings Breakdown: 14 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $174.06 (2.9% Downside)

#7 - NovoCure (NASDAQ:NVCR)

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Read More

Current Stock Price: $47.00
Consensus Rating: Hold
Ratings Breakdown: 3 Buy Ratings, 2 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $84.33 (79.4% Upside)

#8 - Immunovant (NASDAQ:IMVT)

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. Read More

Current Stock Price: $21.04
Consensus Rating: Buy
Ratings Breakdown: 10 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $24.77 (17.7% Upside)

#9 - Roblox (NYSE:RBLX)

Roblox Corporation develops and operates an online entertainment platform. The company offers Roblox Studio, a free toolset that allows developers and creators to build, publish, and operate 3D experiences, and other content; Roblox Client, an application that allows users to explore 3D digital world; Roblox Education for learning experiences; and Roblox Cloud, which provides services and infrastructure that power the human co-experience platform. Read More

Current Stock Price: $41.32
Consensus Rating: Hold
Ratings Breakdown: 12 Buy Ratings, 6 Hold Ratings, 7 Sell Ratings.
Consensus Price Target: $40.22 (2.7% Downside)

#10 - Moderna (NASDAQ:MRNA)

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. Read More

Current Stock Price: $126.90
P/E Ratio: 11.0
Consensus Rating: Hold
Ratings Breakdown: 7 Buy Ratings, 5 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $179.13 (41.2% Upside)

#11 - Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. Read More

Current Stock Price: $40.01
Consensus Rating: Buy
Ratings Breakdown: 13 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $51.50 (28.7% Upside)

#12 - Akero Therapeutics (NASDAQ:AKRO)

Akero Therapeutics, Inc is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. Read More

Current Stock Price: $53.24
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $52.00 (2.3% Downside)

#13 - Cerevel Therapeutics (NASDAQ:CERE)

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. Read More

Current Stock Price: $33.05
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $34.80 (5.3% Upside)

#14 - Galapagos (NASDAQ:GLPG)

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Current Stock Price: $42.41
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $45.37 (7.0% Upside)

#15 - Vaxcyte (NASDAQ:PCVX)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. Read More

Current Stock Price: $51.89
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $65.00 (25.3% Upside)

#16 - Vir Biotechnology (NASDAQ:VIR)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. Read More

Current Stock Price: $26.04
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $49.75 (91.1% Upside)

#17 - Denali Therapeutics (NASDAQ:DNLI)

Denali Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Current Stock Price: $30.58
Consensus Rating: Buy
Ratings Breakdown: 12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $52.09 (70.3% Upside)

#18 - Morphic (NASDAQ:MORF)

Morphic Holding, Inc operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Read More

Current Stock Price: $59.44
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $70.33 (18.3% Upside)

#19 - Revolution Medicines (NASDAQ:RVMD)

Revolution Medicines, Inc, a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. Read More

Current Stock Price: $27.00
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $33.00 (22.2% Upside)

#20 - Prometheus Biosciences (NASDAQ:RXDX)

Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. Read More

Current Stock Price: $198.85
Consensus Rating: Hold
Ratings Breakdown: 4 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $153.36 (22.9% Downside)